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Abstract
Background: Argon plasma coagulation (APC) is typically the first-line therapy for gastric antral vascular ectasia (GAVE).
However, many patients are refractory to APC ablation.
Objective: We examined the safety and efficacy of nitrous oxide CryoBalloon cryotherapy ablation for GAVE refractory to APC.
Methods: This is a retrospective review of patients with refractory GAVE treated with the CryoBalloon system. Technical
success was defined as successful ablation of the visualized GAVE. Clinical success was defined by transfusion independence
and percentage of GAVE that was eradicated.
Results: Twenty-three patients with GAVE were included, of whom 16 patients (70%) had two treatments with the
CryoBalloon and seven patients (30%) had one treatment. Technical success was achieved in all patients. At six months,
19/23 (83%) were transfusion independent, while 20/23 (87%) had more than 75% of the GAVE eradicated. Patients were
transfused an average of 1.8 units/month one year prior to cryotherapy and an average of 0.3 units/month up to six months
post-cryotherapy (p < 0.001). The average increase in mean hemoglobin at six months was 2.55 g/dl. No acute or late
adverse events were reported.
Conclusions: CryoBalloon ablation is an efficacious and safe modality for the treatment of GAVE. Prospective studies need to
be conducted to determine comparative results to standard therapies.
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Key points
. Argon plasma coagulation (APC) is typically ﬁrst-line therapy for gastric antral vascular ectasia (GAVE).
Frequently, multiple APC sessions are required, and some patients are refractory to APC ablation.
. CryoBalloon ablation is an eﬃcacious and safe modality for the treatment of symptomatic refractory GAVE.

Introduction
Gastric antral vascular ectasia (GAVE) is characterized
by longitudinal stripes of ectatic vessels that start at
the pylorus and extend into the antrum or by a diﬀuse
pattern of vessels.1 Although it is an uncommon cause
of bleeding (approximately 4% of nonvariceal upper
gastrointestinal (GI) bleeding), it causes signiﬁcant
morbidity.2 The most common presentation is iron deﬁciency anemia.3 The etiology is unclear, but GAVE is
often seen in patients with renal disease, cirrhosis, cardiac disease, autoimmune disease, and scleroderma.1
The recommended ﬁrst-line treatment for GAVE is
endoscopic ablation with argon plasma coagulation
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(APC).1 However, multiple sessions are required
and rebleeding rates can be as high as 60%.4–6 Other
modalities have been used to treat GAVE, including
radiofrequency ablation (RFA) and liquid nitrogen
cryotherapy (LNC).7,8 Although RFA appears to be
eﬀective,9–11 it may require up to four treatments per
area treated. This is time-consuming and may lead to
post-procedural pain. In addition, frequent removal of
the RFA catheter is required to clean it and to reposition the probe to ablate diﬀerent areas of the stomach.
Frequent passage of the large catheter may be challenging and may predispose to orophyrangeal trauma and
laceration at the gastroesophageal junction.9,12 Spray
cryotherapy has been successfully used to treat patients
with GAVE.13 Drawbacks to this technology include
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limited visibility in the stomach and concerns over ineffective venting of excess nitrogen gas.
Recently, a self-venting balloon-based cryotherapy
has been introduced and is mainly used in treatment
of Barrett’s esophagus.14,15 Advantages over spray
cryotherapy include improved visibility via direct visualization through the balloon and no release of gas into
the stomach. The use of the CryoBalloon for treatment
of GAVE has been described in case report form; however, eﬃcacy and safety data from larger series of
patients are lacking.16 It is our clinical experience that
the CryoBalloon is safe and eﬃcacious for use in APCrefractory GAVE. Thus, the aim of this study is to
report the eﬃcacy and safety of the CryoBalloon for
patients with GAVE refractory to APC in three academic centers with experience using the device for this
indication.

Methods
Participants

Figure 1. Nitrous oxide balloon cryotherapy system. (Image
courtesy of C2 Therapeutics.)

This is a retrospective study on the use of the
CryoBalloon (Coldplay CryoBalloon Focal Ablation
System, C2 Therapeutics, Redwood City, CA
(Figure 1)) in patients with GAVE refractory to APC.
Patients were treated at three tertiary referral academic
medical centers in the United States (Columbia
University Medical Center, NY; Geisinger Medical
Center, Danville, PA; Long Island Jewish Medical
Center, NY). The study was approved by the institutional review (IRB) board at each site from September
5, 2016 to November 9, 2016. Written informed consent
was not required by each patient, per each institution’s
IRB, as this was a retrospective study. The study protocol conforms to the ethical guidelines of the 1975

Figure 2. A patient with watermelon-type gastric antral vascular ectasia: (a) endoscopic view prior to treatment with CryoBalloon; (b)
endoscopic image during CryoBalloon therapy; and (c) endoscopic image at three-month follow-up showing response to therapy.
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Declaration of Helsinki as reﬂected in prior approval
by the institutional review board at each site.
The main outcomes measured were technical, clinical, and endoscopic success. Technical success was
deﬁned as visualization of treatment eﬀect in all
intended areas of treatment. Clinical success was
deﬁned by transfusion independence and percentage
of GAVE that was eradicated. Endoscopic success
was deﬁned as greater than 75% of the GAVE eradicated. Safety was deﬁned with regards to adverse
events. Acute adverse events were deﬁned as events
occurring during the procedure and recorded per the
American Society for Gastrointestinal Endoscopy
(ASGE) lexicon.10 Late adverse events were deﬁned as
events identiﬁed after being discharged home from the
hospital. These adverse events were captured by chart
abstraction and review. Demographic information was
collected, as well as prior medical and endoscopic management of GAVE. Refractory cases were patients who
failed to respond to treatment with APC for a minimum of two separate endoscopic sessions.
Patients were included in this study if there was (1)
endoscopic evidence of GAVE, (2) the presence of
either anemia or evidence of overt upper GI bleeding
(e.g. melena or hematemesis), (3) GAVE previously
treated with APC, (4) a minimum of four weeks that
had passed since the last treatment of APC, and (5) at
least six months of follow-up. Patients were excluded if
they were under 18 years old or were a member of a
vulnerable population.

Specifics of CryoBalloon cryotherapy
The CryoBalloon Focal Ablation System consists of a
balloon-tip catheter that attaches to a battery-powered,
hand-held controller.14 The controller contains a 23.5 g
liquid nitrous oxide cartridge. The balloon catheter is
advanced through the channel of a therapeutic endoscope (>3.7 mm channel) and the balloon is inﬂated to
approximately 25–30 mm by pulling the trigger of the
controller.14 The inﬂated 3 cm long balloon contacts the
mucosa to be ablated. Holding the trigger delivers
nitrous oxide cryogen for a predetermined variable
length of time that is preselected on the controller
(Figure 2). The cryogen is contained within the balloon,
and therefore a separate decompression tube is not
necessary.

Endoscopic procedure/treatment
Informed consent was obtained from all patients.
Moderate sedation with intravenous fentanyl and midazolam or monitored anesthesia care with propofol
was administered based on physician preference and
patient characteristics. The C2 Therapeutics single-
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use focal CryoBalloon, 3.6 mm diameter catheter
(Redwood City, CA) was passed through a therapeutic
endoscopic channel. The endoscope was advanced to
the antrum of the stomach. The balloon catheter was
connected to the portable, small, battery-powered
handle that electronically controls the diﬀuser and
holds the single-use liquid nitrous oxide canister. To
allow visualization of the gastric mucosa through the
transparent balloon, the trigger on the handle was
pressed to deliver a one-second release of liquid nitrous
oxide (‘‘pre-puﬀ’’), which evaporates and inﬂates the
balloon. The balloon catheter was positioned with its
proximal end in contact with the endoscope tip. The
‘‘pre-puﬀ’’ and resulting ice patch enabled visualization
of the direction of the spray and allowed precise targeting. The cryogen was then directed to the targeted area
by rotating the delivery catheter in the balloon clockwise or counterclockwise. After the ‘‘pre-puﬀ,’’ the trigger of the handle was pressed and the cryogen was
delivered for a preset number of seconds. A cryogen
dosimetry of 10 or 14 seconds was used based on previous clinical experience and a clinical trial involving
cryoablation in patients with Barrett’s esophagus.15
After cryoablation, routine medications were continued and diet was advanced as tolerated. Proton pump
inhibitors or sucralfate (1 g three times a day, tablet or
slurry) was prescribed according to each site’s standard
postablation clinical protocol. Analgesics were not routinely prescribed. All patients had hemoglobin levels
checked post-CryoBalloon therapy at three and six
months. Patients who had ongoing symptoms of
anemia had more frequent laboratory surveillance.

Data collection and analysis
All analyses were conducted using SAS version 24 (SAS
Institute Inc, Cary, NC).
The data for the following variables were collected
for each patient: age, sex, previous or concurrent treatments, adverse events, number of treatment sessions,
and results of cryotherapy. All individuals and treatments were assessed for the safety analysis using the
ASGE adverse events grading system.10 Categorical
variables were analyzed using chi squared analyses,
and numerical variables were calculated using the
mean or median where appropriate. A two-tailed p
value of <0.05 was considered signiﬁcant. Mean and
standard deviation (SD) or mean and interquartile
range (IQR) are reported for continuous variables.
Proportions are reported for categorical variables.

Results
Twenty-three patients were included in the analysis.
Patient characteristics can be found in Table 1.
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Table 1. Patient characteristics.

Table 2. Patient outcomes.
Total N ¼ 23

Gender
Female
Male
Age
Mean
SD
Etiology
Portal hypertension
Renal
Collagen vascular
Idiopathic
Presentation
Anemia
Melena
Occult bleeding
Pattern of GAVE
Watermelon appearance
Diffuse
Percentage of antrum involvement
0%–25%
25%–49%
50%–75%
76%–100%
Prior treatment
APC
RFA

16/23 (70%)
07/23 (30%)
71.7
10.2
10/23(43.5%)
1/23 (4%)
2/23 (9%)
10/23(43.5%)
23/23 (100%)
14/23 (61%)
6/23 (26%)
18/23 (78%)
5/23 (22%)
1/23
0/23
5/23
17/23

(4%)
(0%)
(22%)
(74%)

23/23 (100%)
7/23 (30%)

APC: argon plasma coagulation; GAVE: gastric antral vascular ectasia; RFA:
radiofrequency ablation.

Sixteen patients were female and the mean age was 71.7
years (SD 10.2 years). All patients presented with
anemia and 14 presented with melena. All patients
were refractory to prior treatment with APC based on
our criteria. Seven patients had also undergone RFA
treatment, with no improvement, and were thus considered RFA refractory as well. The gastric antrum
was involved in all patients and the gastric cardia in
one. None of the patients had evidence of involvement
elsewhere in the stomach and thus were consistent with
GAVE, as opposed to portal hypertensive gastropathy,
which can be seen throughout the stomach.1,17
Seventeen patients were treated with initial 14-second
dosing and six were treated with 10-second dosing.
Sixteen patients (70%) had two treatments with the
CryoBalloon and seven patients (30%) had one treatment. Out of the seven patients who had one treatment,
three patients (50% of the 10-second group) had
10-second dosing and four (24% of the 14-second
group) had 14-second dosing (50% vs 24%, p ¼ 0.25).

N ¼ 23
Technical success (34 CryoBalloon
procedures)
Clinical success (defined as transfusion
independent following CryoBalloon)
At three months
At six months
Endoscopic success (defined as 75% of
GAVE eradicated)
At three months
At six months
Average number of blood transfusions
per month prior to and post-initial
CryoBalloon
One year prior to CryoBalloon ablation
Six months after CryoBalloon ablation
Average increase in mean hemoglobin
Six months after CryoBalloon ablation

100%

11/23 (48%)
19/23 (83%)

9/23 (39%)
20/23 (87%)

1.76 units
0.31 units
2.55 g/dl

GAVE: gastric antral vascular ectasia.

CryoBalloon therapy outcomes can be found in
Table 2. Technical success was achieved in all patients.
Patients were transfused an average of 1.8 units/month
one year prior to cryotherapy and an average of
0.3 units/month up to six months post-cryotherapy,
which was statistically signiﬁcant (p < 0.001). Average
increase in mean hemoglobin at six months was
2.55 g/dl. At three months, 11 out of 23 (48%) were
transfusion independent, and nine out of 23 (39%)
had more than 75% of the GAVE eradicated. At six
months, 19 out of 23 (83%) were transfusion independent, while 20 out of 23 (87%) had more than 75% of the
GAVE eradicated.
In comparing the 10-second dosing vs the 14-second
dosing, there were no statistical diﬀerences between the
two groups in regards to clinical and endoscopic success
at three months or six months. The three-month clinical
success rates were 17% vs 59% (1/6 vs 10/17, p ¼ 0.08)
for the 10-second and 14-second dosing, respectively.
The six-month clinical success rates were 67% vs 88%
(4/6 vs 15/17, p ¼ 0.26) for the 10-second and 14-second
dosing, respectively. The three-month endoscopic success rates were 17% vs 47% (1/6 vs 8/17, p ¼ 0.2) for
the 10-second and 14-second dosing, respectively. The
six-month endoscopic success rates were 67% vs 94%
(4/6 vs 16/17, p ¼ 0.26) for the 10-second and 14-second
dosing, respectively.
There were no acute adverse events that were
observed at the time of endoscopy or in the recovery
area. On review of follow-up appointment notes, no
late adverse events were discovered.
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Discussion
APC is the mainstay of treatment for GAVE. However,
around two-thirds of patients treated with APC remain
reliant on blood transfusions.18 This study shows
that nitrous oxide CryoBalloon ablation is both eﬃcacious and safe for patients with GAVE refractory to
treatment with APC. The vast majority of patients
achieved both transfusion independence and endoscopic response at six months (83% and 87%, respectively). At the three-month time point, 48% of patients
were transfusion independent while 39% achieved
endoscopic ablation success. Further prospective data
are needed to understand the optimal length of therapy
and factors predicting response.
There are many notable advantages to CryoBalloon
therapy. Treatment requires a single passage of the
endoscope. Only one ablation per site is required, minimizing ablation times. Another advantage is that ablation of the GAVE is clearly visualized throughout the
entire process, which may not always occur with other
cryotherapy platforms. After ablation, a deep erythema
is visualized and selection of the next target site is
straightforward. Finally, CryoBalloon ablation does
not require a costly console or generator, and does
not require time-consuming, cumbersome reﬁlling of a
cryogen. Thus, it is relatively easy to perform and may
be accessible to a larger number of providers.
The anatomic distribution of GAVE is well suited
for CryoBalloon ablation. GAVE usually involves
the antrum but it can occasionally involve the gastric
cardia, unlike portal hypertensive gastropathy, which
can involve any part of the stomach.1,17,19 It is this
anatomical distribution of GAVE that makes the
use of the CryoBalloon appealing for therapy. It is
easier to appose the mucosa of the antrum and cardia
against the balloon compared to other parts of the
stomach.
In comparing CryoBalloon to RFA for APC-refractory GAVE, both modalities appear to be eﬃcacious.
In the largest prospective series evaluating 21 patients
who underwent RFA for APC-refractory disease, the
technical success and clinical success rates were 90%
and 86%, respectively.9 This is comparable to our
study of 23 patients in which the technical and clinical
success rates were 100% and 83%, respectively. The
beneﬁts of CryoBalloon over RFA include the portable
nature of the device, the lack of expensive capital equipment (e.g. RFA generator), and the fewer number
of ablations required in CryoBalloon over RFA. The
CryoBalloon requires only one ablation per area treated vs up to four in RFA. Finally, the RFA probe is
attached to the end of the gastroscope and may need to
be removed frequently for cleaning. The CryoBalloon is
inserted in the channel and is not removed until the
procedure is completed.
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LNC has also been studied in a limited capacity
for GAVE. A prospective study of 12 patients, eight
of whom were refractory to APC, showed LNC can
be eﬀective for GAVE eradication. Technical success
was achieved in 89% while the mean rise in hemoglobin was from 9.9 to 11.3 g/dl. This small study is
the largest study to date. In our experience, LNC
for GAVE is challenging because of visibility issues.
The lumen of the stomach is large and poor visibility
occurs rather quickly. In addition, given the larger
lumen, excess gas accumulation can occur quickly, despite the decompression tube. These challenges do not
occur in the CryoBalloon thanks to the self-venting
balloon design.
There are limitations to this study. The study is retrospective and thus subject to inherit limitations of this
study design. One of these limitations is that retrospective studies may not capture minor late adverse events
well as patients are not being prospectively followed to
speciﬁcally screen for this. An example of this is postprocedural pain. Patients may have tolerable pain that
keeps them out of the hospital but does aﬀect their
daily routine. This would not be captured well in this
study design. That being said, these patients had close
follow-up with their endoscopist for blood work and
repeat procedures; no serious late adverse events were
described in the patient charts. Another limitation is
that the overall number of patients is small. However,
one may consider this a relatively large cohort for a
GAVE study, given that GAVE occurs in only 4% of
nonvariceal upper GI bleeding.1 Despite these limitations, the value and utility of CryoBalloon ablation for
this cohort of patients was demonstrated in this study.
Larger and prospective studies are needed to conﬁrm
our ﬁndings in the future.
In conclusion, this multicenter clinical experience
suggests that nitrous oxide cryotherapy using a portable, novel contact focal cryoablation balloon is a safe
and eﬀective treatment option in the management of
GAVE. Further studies must be conducted to evaluate
the long-term eﬀects of this modality in the management of GAVE. Comparative eﬀectiveness trials might
eventually determine the role of cryoablation in the
treatment of GAVE and the potential role for its use
earlier in the management of GAVE.
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